News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
HBM HOLDINGS-B (02142.HK): IND for HBM7004 in Advanced Solid Tumors Approved by FDA
HBM HOLDINGS-B (02142.HK) announced that it has obtained approval from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application and will initiat...
Reset
Send
The window will close in 5 seconds
HBM HOLDINGS-B (02142.HK): IND for HBM7004 in Advanced Solid Tumors Approved by FDA
Close
Recommend
2
Positive
2
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Gold ETF share!

HBM HOLDINGS-B (02142.HK)  +0.080 (+0.628%)    Short selling $5.99M; Ratio 16.773%   announced that it has obtained approval from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application and will initiate a first-in-human Phase I clinical trial in the United States for its novel B7H4xCD3 bispecific antibody HBM7004. The Phase I study will evaluate the safety, tolerability, pharmacokinetic profile and preliminary anti-tumor activity of HBM7004 in patients with advanced solid tumors.

HBM7004 is a novel B7H4xCD3 bispecific antibody developed using the Groups proprietary HBICE?platform, offering differentiated solutions for cancer immunotherapy in terms of both efficacy and safety.


HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-15 16:25
Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.